checkAd
    Protagonist Therapeutics Aktie
    33,17
     
    USD
    -4,68 %
    -1,63 USD
    Letzter Kurs 02:00:00 Nasdaq
    33,17
     
    USD
    3.900 STK
    Geldkurs 10.06.24
    33,23
     
    USD
    1.200 STK
    Briefkurs 10.06.24
    ISIN: US74366E1029 · WKN: A2AP32 · SYM: PTGX · USA

    Neueste Nachrichten

    Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024
    31.05.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress
    14.05.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event
    07.05.24 · Accesswire · Protagonist Therapeutics
    Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
    07.05.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
    26.03.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
    18.03.24 · Accesswire · Protagonist Therapeutics
    Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
    11.03.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics to Participate in Upcoming Investor Conferences
    06.03.24 · Accesswire · Protagonist Therapeutics
    Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    27.02.24 · Accesswire · Protagonist Therapeutics
    New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
    21.02.24 · Accesswire · Protagonist Therapeutics
    Protagonist Therapeutics Reports Granting of Inducement Awards
    20.02.24 · Accesswire · Protagonist Therapeutics
    Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis
    13.12.23 · Accesswire · Protagonist Therapeutics